S&P 500   4,352.75 (+0.53%)
DOW   34,129.17 (+0.17%)
QQQ   361.26 (+0.95%)
AAPL   176.46 (+1.45%)
MSFT   320.45 (+0.29%)
META   302.63 (+2.33%)
GOOGL   131.68 (+0.95%)
AMZN   131.60 (+1.76%)
TSLA   255.13 (-0.22%)
NVDA   419.96 (+2.39%)
NIO   8.57 (+1.42%)
BABA   88.16 (+4.82%)
AMD   98.04 (+2.01%)
T   15.06 (-1.63%)
F   12.54 (+2.79%)
MU   69.21 (+1.93%)
CGC   0.82 (+7.14%)
GE   112.91 (-0.07%)
DIS   82.18 (-0.66%)
AMC   7.94 (+3.12%)
PFE   32.78 (-0.21%)
PYPL   58.80 (+0.31%)
NFLX   383.73 (-0.11%)
S&P 500   4,352.75 (+0.53%)
DOW   34,129.17 (+0.17%)
QQQ   361.26 (+0.95%)
AAPL   176.46 (+1.45%)
MSFT   320.45 (+0.29%)
META   302.63 (+2.33%)
GOOGL   131.68 (+0.95%)
AMZN   131.60 (+1.76%)
TSLA   255.13 (-0.22%)
NVDA   419.96 (+2.39%)
NIO   8.57 (+1.42%)
BABA   88.16 (+4.82%)
AMD   98.04 (+2.01%)
T   15.06 (-1.63%)
F   12.54 (+2.79%)
MU   69.21 (+1.93%)
CGC   0.82 (+7.14%)
GE   112.91 (-0.07%)
DIS   82.18 (-0.66%)
AMC   7.94 (+3.12%)
PFE   32.78 (-0.21%)
PYPL   58.80 (+0.31%)
NFLX   383.73 (-0.11%)
S&P 500   4,352.75 (+0.53%)
DOW   34,129.17 (+0.17%)
QQQ   361.26 (+0.95%)
AAPL   176.46 (+1.45%)
MSFT   320.45 (+0.29%)
META   302.63 (+2.33%)
GOOGL   131.68 (+0.95%)
AMZN   131.60 (+1.76%)
TSLA   255.13 (-0.22%)
NVDA   419.96 (+2.39%)
NIO   8.57 (+1.42%)
BABA   88.16 (+4.82%)
AMD   98.04 (+2.01%)
T   15.06 (-1.63%)
F   12.54 (+2.79%)
MU   69.21 (+1.93%)
CGC   0.82 (+7.14%)
GE   112.91 (-0.07%)
DIS   82.18 (-0.66%)
AMC   7.94 (+3.12%)
PFE   32.78 (-0.21%)
PYPL   58.80 (+0.31%)
NFLX   383.73 (-0.11%)
S&P 500   4,352.75 (+0.53%)
DOW   34,129.17 (+0.17%)
QQQ   361.26 (+0.95%)
AAPL   176.46 (+1.45%)
MSFT   320.45 (+0.29%)
META   302.63 (+2.33%)
GOOGL   131.68 (+0.95%)
AMZN   131.60 (+1.76%)
TSLA   255.13 (-0.22%)
NVDA   419.96 (+2.39%)
NIO   8.57 (+1.42%)
BABA   88.16 (+4.82%)
AMD   98.04 (+2.01%)
T   15.06 (-1.63%)
F   12.54 (+2.79%)
MU   69.21 (+1.93%)
CGC   0.82 (+7.14%)
GE   112.91 (-0.07%)
DIS   82.18 (-0.66%)
AMC   7.94 (+3.12%)
PFE   32.78 (-0.21%)
PYPL   58.80 (+0.31%)
NFLX   383.73 (-0.11%)
NYSE:EW

Edwards Lifesciences (EW) Stock Forecast, Price & News

$70.28
+0.10 (+0.14%)
(As of 11:34 AM ET)
Compare
Today's Range
$69.65
$70.74
50-Day Range
$71.95
$93.38
52-Week Range
$67.13
$94.87
Volume
735,133 shs
Average Volume
3.16 million shs
Market Capitalization
$42.72 billion
P/E Ratio
31.10
Dividend Yield
N/A
Price Target
$92.42

Edwards Lifesciences MarketRank™ Forecast

Analyst Rating
Hold
2.39 Rating Score
Upside/​Downside
32.2% Upside
$92.42 Price Target
Short Interest
Healthy
1.79% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.95
Upright™ Environmental Score
News Sentiment
0.64mentions of Edwards Lifesciences in the last 14 days
Based on 16 Articles This Week
Insider Trading
Selling Shares
$14.30 M Sold Last Quarter
Proj. Earnings Growth
12.94%
From $2.55 to $2.88 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.02 out of 5 stars

Medical Sector

31st out of 964 stocks

Medical Devices Industry

1st out of 6 stocks


EW stock logo

About Edwards Lifesciences (NYSE:EW) Stock

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

EW Price History

EW Stock News Headlines

Why Analysts Say GE's Healthcare Spinoff Has $20 Upside (EW)
General Electric’s spinoff, GE HealthCare Technologies Inc., is delivering some impressive results and has growth opportunities well worth tuning in to.
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Edwards Lifesciences (EW) Gets a Hold from Bank of America Securities
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Edwards Lifesciences (NYSE:EW) Lowered to "Hold" at StockNews.com
See More Headlines
Receive EW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter.

EW Company Calendar

Last Earnings
7/26/2023
Today
9/22/2023
Next Earnings (Estimated)
10/26/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medical Devices
Sub-Industry
Health Care Equipment
Sector
Medical
CUSIP
28176E10
Employees
17,300
Year Founded
1958

Price Target and Rating

Average Stock Price Forecast
$92.42
High Stock Price Forecast
$110.00
Low Stock Price Forecast
$66.00
Forecasted Upside/Downside
+31.3%
Consensus Rating
Hold
Rating Score (0-4)
2.39
Research Coverage
18 Analysts

Profitability

Net Income
$1.52 billion
Pretax Margin
28.35%

Debt

Sales & Book Value

Annual Sales
$5.38 billion
Cash Flow
$2.67 per share
Book Value
$9.39 per share

Miscellaneous

Free Float
600,074,000
Market Cap
$42.80 billion
Optionable
Optionable
Beta
1.03

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Bernard J. ZovighianMr. Bernard J. Zovighian (Age 55)
    CEO & Director
    Comp: $1.04M
  • Mr. Scott B. UllemMr. Scott B. Ullem (Age 56)
    Corp. VP & CFO
    Comp: $1.09M
  • Mr. Larry L. WoodMr. Larry L. Wood (Age 57)
    Corp. VP and Group Pres of TAVR & Surgical Structural Heart
    Comp: $1.1M
  • Mr. Jean-Luc LemercierMr. Jean-Luc Lemercier (Age 66)
    Corp. VP of Japan, Asia Pacific & Greater China
    Comp: $1.24M
  • Dr. Todd J. Brinton FACC
    M.D., Corp. VP of Advanced Technology & Chief Scientific Officer
  • Mark Wilterding
    VP of Investor Relations
  • Mr. Arnold A. Pinkston (Age 64)
    Corp. VP & Gen. Counsel
  • Mr. Dirksen J. Lehman
    Corp. VP of Public Affairs
  • Mr. Donald E. Bobo Jr.Mr. Donald E. Bobo Jr. (Age 61)
    Corp. VP of Strategy & Corp. Devel.
  • Ms. Christine Z. McCauley (Age 58)
    Corp. VP of HR













EW Stock - Frequently Asked Questions

Should I buy or sell Edwards Lifesciences stock right now?

18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 1 sell rating, 9 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" EW shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EW, but not buy additional shares or sell existing shares.
View EW analyst ratings
or view top-rated stocks.

What is Edwards Lifesciences' stock price forecast for 2023?

18 Wall Street research analysts have issued 1-year target prices for Edwards Lifesciences' shares. Their EW share price forecasts range from $66.00 to $110.00. On average, they expect the company's stock price to reach $92.42 in the next twelve months. This suggests a possible upside of 31.3% from the stock's current price.
View analysts price targets for EW
or view top-rated stocks among Wall Street analysts.

How have EW shares performed in 2023?

Edwards Lifesciences' stock was trading at $74.61 at the start of the year. Since then, EW stock has decreased by 5.6% and is now trading at $70.40.
View the best growth stocks for 2023 here
.

Are investors shorting Edwards Lifesciences?

Edwards Lifesciences saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 10,750,000 shares, an increase of 13.0% from the August 15th total of 9,510,000 shares. Based on an average daily trading volume, of 3,190,000 shares, the days-to-cover ratio is presently 3.4 days. Currently, 1.8% of the company's shares are sold short.
View Edwards Lifesciences' Short Interest
.

When is Edwards Lifesciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023.
View our EW earnings forecast
.

How were Edwards Lifesciences' earnings last quarter?

Edwards Lifesciences Co. (NYSE:EW) announced its quarterly earnings data on Wednesday, July, 26th. The medical research company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.65 by $0.01. The medical research company earned $1.53 billion during the quarter, compared to analysts' expectations of $1.51 billion. Edwards Lifesciences had a trailing twelve-month return on equity of 25.43% and a net margin of 24.56%. The firm's revenue for the quarter was up 11.4% on a year-over-year basis. During the same quarter last year, the company posted $0.63 EPS.
Read the conference call transcript
.

When did Edwards Lifesciences' stock split?

Shares of Edwards Lifesciences split on Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly issued shares were issued to shareholders after the closing bell on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.

What guidance has Edwards Lifesciences issued on next quarter's earnings?

Edwards Lifesciences updated its third quarter 2023 earnings guidance on Wednesday, July, 26th. The company provided earnings per share (EPS) guidance of $0.55-$0.61 for the period, compared to the consensus estimate of $0.63. The company issued revenue guidance of $1.44 billion-$1.52 billion, compared to the consensus revenue estimate of $1.47 billion.

What is Michael A. Mussallem's approval rating as Edwards Lifesciences' CEO?

389 employees have rated Edwards Lifesciences Chief Executive Officer Michael A. Mussallem on Glassdoor.com. Michael A. Mussallem has an approval rating of 90% among the company's employees.

What other stocks do shareholders of Edwards Lifesciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Home Depot (HD), Salesforce (CRM), Walt Disney (DIS), Visa (V), Johnson & Johnson (JNJ), QUALCOMM (QCOM), Micron Technology (MU) and CVS Health (CVS).

What is Edwards Lifesciences' stock symbol?

Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

Who are Edwards Lifesciences' major shareholders?

Edwards Lifesciences' stock is owned by many different institutional and retail investors. Top institutional investors include Bank Julius Baer & Co. Ltd Zurich (125.25%), BlackRock Inc. (8.36%), State Street Corp (4.45%), Capital International Investors (4.44%), Alliancebernstein L.P. (3.37%) and Bank of New York Mellon Corp (2.91%). Insiders that own company stock include Bernard J Zovighian, Catherine M Szyman, Catherine M Szyman, Daveen Chopra, Donald E Bobo Jr, Heisz Leslie Stone, Huimin Wang, Jean-Luc M Lemercier, Kieran Gallahue, Larry L Wood, Martha H Marsh, Michael A Mussallem, Michael A Mussallem, Nicholas J Valeriani, Robert WA Sellers and Scott B Ullem.
View institutional ownership trends
.

How do I buy shares of Edwards Lifesciences?

Shares of EW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Edwards Lifesciences' stock price today?

One share of EW stock can currently be purchased for approximately $70.40.

How much money does Edwards Lifesciences make?

Edwards Lifesciences (NYSE:EW) has a market capitalization of $42.80 billion and generates $5.38 billion in revenue each year. The medical research company earns $1.52 billion in net income (profit) each year or $2.26 on an earnings per share basis.

How many employees does Edwards Lifesciences have?

The company employs 17,300 workers across the globe.

Does Edwards Lifesciences have any subsidiaries?
The following companies are subsidiares of Edwards Lifesciences: BMEYE, CAS Medical Systems, CardiAQ Valve Technologies, Edwards Lifesciences (Japan) Limited, Edwards Lifesciences AG, Edwards Lifesciences Holding B.V., Edwards Lifesciences Innovation Holding LLC, Edwards Lifesciences LLC, Edwards Lifesciences Services GmbH, Embrella Cardiovascular, Harpoon Medical, Myocor, Percutaneous Valve Technologies, Valtech Cardio, and Whitland Research.
Read More
How can I contact Edwards Lifesciences?

Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The official website for the company is www.edwards.com. The medical research company can be reached via phone at (949) 250-2500, via email at investor_relations@edwards.com, or via fax at 949-250-2525.

This page (NYSE:EW) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -